Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model

Movement Disorders

Volumn 15, Issue 3, 2000, Pages 459-466

  Di Monte, Donato A ^a   McCormack, Alison ^a,b   Petzinger, Giselle ^a   Janson, Ann Marie ^a,b   Quik, Maryka ^a   Langston, William J ^a  

^a PARKINSON S INSTITUTE   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Dopamine; Dyskinesias; Levodopa; Monkeys; MPTP; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; DOPAMINE TRANSPORTER; LEVODOPA; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LOSS; CONTROLLED STUDY; DENERVATION; DISEASE SEVERITY; DOPAMINE RELEASE; DOPAMINE UPTAKE; DOPAMINERGIC NERVE CELL; DYSKINESIA; INVOLUNTARY MOVEMENT; NERVE INJURY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSONISM; PRIMATE; PRIORITY JOURNAL; SQUIRREL MONKEY;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIPARKINSON AGENTS; BRAIN MAPPING; CORPUS STRIATUM; DENERVATION; DOPAMINE; DYSKINESIA, DRUG-INDUCED; LEVODOPA; NEURONS; PARKINSON DISEASE, SECONDARY; RECEPTORS, DOPAMINE; SAIMIRI; SUBSTANTIA NIGRA;

EID: 0034114557     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8257(200005)15:3<459::AID-MDS1006>3.0.CO;2-3     Document Type: Article

References (35)

1. Nutt JG. Levodopa-induced dyskinesia: review, observations, and speculations. Neurology 1990;40:340-345.
2. Poewe W. Clinical and pathophysiologic aspects of late levodopa failure. Neurology 1993;43:S28-S30.
3. Langston JW, Ballard P. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease. Can J Neurol Sci 1984;11:160-165.
4. Caligiuri MP, Lohr JB. Worsening of postural tremor in patients with levodopa-induced dyskinesia: a quantitative analysis. Clin Neuropharmacol 1993;16:244-250.
5. Murphy MJ. L-Dopa induced dyskinesias in asymmetrical parkinsonism. Acta Neurol Latinoam 1979;25:47-52.
6. Horstink MW, Zijlmans JC, Pasman JW, Berger HJ, van't Hof MA. Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia. J Neurol Neurosurg Psychiatry 1990;53:224-226.
7. Di Monte DA, Langston JW. MPTP-induced parkinsonism in non-human primates. In: Schneider JS, Gupta M, eds. Current Concepts in Parkinson's Disease Research. Kirkland, WA: Hogrefe & Huber Publishers, 1993:159-179.
8. Clarke CE, Sambrook MA, Mitchell IJ, Crossman AR. Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahdropyridine (MPTP). J Neurol Sci 1987;78:273-280.
9. Schneider JS. Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage. Pharmacol Biochem Behav 1989;34:193-196.
10. Boyce S. Rupniak NMJ, Steventon MJ, Iversen SD. Nigrostriatal damage is required for induction of dyskinesias by L-dopa in squirrel monkeys. Clin Neuropharmacol 1990;13:448-458.
11. A receptors in the striatopallidal complex. Brain Res 1995;680:43-52.
12. Pearce RKB, Jackson M, Smith L, Jenner P. Marsden CD. Chronic L-dopa administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus). Mov Disord 1995;10:731-740.
13. Chase TN. Levodopa therapy: consequences of nonphysiologic replacement of dopamine. Neurology 1998;50:S17-S25.
14. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973;20:415-455.
15. Lloyd KG, Davidson L, Hornykiewicz O. The neurochemistry of Parkinson's disease: effect of L-dopa therapy. J Pharmacol Exp Ther 1975;195:453-564.
16. Alexander GM, Schwartzman RJ, Brainard L, Gordon SW. Changes in brain catecholamines and dopamine uptake sites at different stages of MPTP parkinsonism in monkeys. Brain Res 1992;588:261-269.
17. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 1988;318:876-880.
18. Irwin I, DeLanney LE, Forno LS, Finnegan KT, Di Monte DA, Langston JW. The evolution of nigrostriatal neurochemical changes in the MPTP-treated squirrel monkey. Brain Res 1990; 531:242-252.
19. Lowry OH, Rosebrough JJ, Farr AL, Randall RJ. Protein measurement with the Folin reagent. J Biol Chem 1951;193:265-275.
20. Kilpatrick IC, Jones MW, Phillipson OT. A semiautomated analysis method for catecholammes, indoleamines, and some prominent metabolites in microdissected regions of the nervous system: an isocratic HPLC technique employing coulometric detection and minimal sample preparation. J Neurochem 1986;46:1865-1876.
21. Janson AM, Møller A. Chronic nicotine treatment counteracts nigral cell loss induced by a partial meso-diencephalic hemitransection. An analysis of the total number and mean volume of neurons and glia in substantia nigra of the male rat. Neuroscience 1993; 57:931-941.
22. Chan P, Di Monte DA, Langston JW, Janson AM. (+)MK-801 does not prevent MPTP-induced loss of nigral neurons in mice. J Pharmacol Exp Ther 1997;280:439-446.
23. West M, Slomianka L, Gundersen HJG. Unbiased stereological estimation of the total number of neurons in the subdivisions of rat hippocampus using the optical fractionator. Anat Rec 1991;231: 482-497.
24. Walters TL, Irwin I, Delfani K, Langston JW, Janson AM. Diethyldithiocarbamate causes nigral cell loss and dopamine depletion with nontoxic doses of MPTP. Exp Neurol 1999;156:62-70.
25. Gundersen HJ, Jensen EB. The efficiency of systematic sampling in stereology and its prediction. J Microsc 1987;147:229-263.
26. 125I]iodophenyl)tropane-2β-carboxylic acid isopropyl ester. Mol Pharmacol 1995;47:779-786.
27. Henry B, Crossman AR, Brotchie JM. Characterization of enhanced behavioral responses to L-dopa following repeated administration in the 6-hydroxydupamine-lesioned rat model of Parkinson's disease. Exp Neurol 1998;151:334-342.
28. Langston JW, Quik MQ, Petzinger G, Jakowec M. Di Monte DA. Investigating levodopa-induced dyskinesias in the parkinsonian primate. Ann Neurol 2000. In press.
29. Abnormal involuntary movement scale (AIMS). Psychopharmacol Bull 1988;24:781-783.
30. Markham CH. The choreoathetoid movement disorder induced by levodopa. Clin Pharmacol Ther 1971;12:340-343.
31. Quinn N, Critchley P, Marsden CD. Young onset Parkinson's disease. Mov Disord 1987;2:73-91.
32. Mones RJ. Experimental dyskinesias in normal rhesus monkeys. In: Barbeau A, Chase TN, Paulson GW. eds. Advances in Neurology, vol 1. New York, NY: Raven Press, 1973:665-669.
33. Sassin JF. Drug-induced dyskinesias in monkeys. In: Meldrum BS, Marsden CD, eds. Advances in Neurology, vol 10. New York, NY: Raven Press, 1975:47-54.
34. Bedard PJ. Mancilla BG, Blanchette P, Gagnon C. Di Paolo T. Levodopa-induced dyskinesia: facts and fancy. What does the MPTP monkey model tell us? Can J Neurol Sci 1992;19:134-137.
35. Pearce RKB. L-Dopa and dyskinesias in normal monkeys. Mov Disord 1999;14(suppl 1):9-12.